The HF-HRV Registry

This study has been completed.
Information provided by:
Boston Scientific Corporation Identifier:
First received: September 2, 2005
Last updated: November 13, 2006
Last verified: October 2005
The Registry will evaluate how HRV Monitor diagnostics change after cardiac resynchronization therapy in patients with heart failure.

Condition Intervention Phase
Heart Failure
Device: Cardiac Resynchronization Therapy
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: CONTAK RENEWAL® Heart Failure Heart Rate Variability Registry

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Estimated Enrollment: 1400
Study Start Date: February 2003
Estimated Study Completion Date: May 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients receiving their first CRT-D
  • Patients who sign and date a Patient Informed Consent prior to device implant
  • Patients who are available and willing to attend follow-up visits at the study center in which they were enrolled

Exclusion Criteria:

  • Patients who are anticipated to receive pacing modes other than DDD or VDD (i.e., chronic atrial fibrillation patients are excluded), or patients who are anticipated to receive adaptive rate therapy
  • Patients who are younger than 18 years of age
  • Patients whose life expectancy is less than six-months due to other medical conditions
  • Patients with or who are likely to receive a tricuspid or other valve prosthesis
  • Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study
  • Women who are pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00236236

Sponsors and Collaborators
Boston Scientific Corporation
Study Chair: Kellie Chase Guidant Corporation
  More Information

No publications provided Identifier: NCT00236236     History of Changes
Other Study ID Numbers: CR-CA-022103-H 
Study First Received: September 2, 2005
Last Updated: November 13, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases processed this record on February 04, 2016